| 27.09 14:49 | dpa-AFX: Johnson & Johnson Reports New Data From Phase 1b TRIMM-2 Study |
| 27.09 14:30 | dpa-AFX: J&J Reports Data From Investigational Phase 1b RedirecTT-1 Study |
| 27.09 14:10 | dpa-AFX: *J&J : TALVEY AND TECVAYLI SHOW HIGH RESPONSE RATES IN TRIPLE-CLASS REFRACTORY MULTIPLE MYELOMA |
| 27.09 14:07 | dpa-AFX: *JOHNSON & JOHNSON ANNOUNCES PHASE 1B TRIMM-2 RESULTS EVALUATING TALVEY WITH DARZALEX FASPRO |
| 27.09 09:34 | EU-Zulassung für Stelara-Biosimilar von Formycon und Fresenius Kabi |
| 21.09 07:21 | dpa-AFX: J&J's Subsidiary Red River Talc Files For Chapter 11 Bankruptcy To Resolve Ovarian Cancer Claims |
| 20.09 14:04 | dpa-AFX: Janssen-Cilag Reports CHMP Recommendation For Daratumumab |
| 20.09 13:43 | dpa-AFX: *J&J : DARZALEX QUADRUPLET REGIMEN GETS POSITIVE CHMP OPINION FOR NEWLY DIAGNOSED MYELOMA PATIENTS |
| 20.09 02:47 | dpa-AFX: FDA Okays J&J's RYBREVANT For Advanced Non-Small Cell Lung Cancer In Combination With Chemotherapy |
| 16.09 09:33 | dpa-AFX: Johnson & Johnson Reports Promising Interim Data From Phase 2 SunRISe-4 Study |
| 16.09 08:55 | dpa-AFX: *J&J ANNOUNCES INTERIM DATA FROM PHASE 2 SUNRISE-4 STUDY OF TAR-200 COMBINATION IN MUSCLE-INVASIVE BLADDER CANCER |
| 15.09 10:15 | dpa-AFX: J&J's TAR-200 Phase 2b SunRISe-1 Study Shows 84% Complete Response In High-Risk Bladder Cancer |
| 14.09 16:39 | dpa-AFX: J&J Announces Promising Phase 1b/2 Data For Amivantamab Combination In Metastatic Colorectal Cancer |
| 14.09 09:54 | dpa-AFX: J&J: RYBREVANT + Chemotherapy Shows Strong Benefits And Improved Survival In Phase 3 NSCLC Trial |
| 13.09 07:20 | dpa-AFX: *HSBC RAISES JOHNSON & JOHNSON PRICE TARGET TO 180 (174) USD - 'BUY' |
| 13.09 07:20 | dpa-AFX: *HSBC HEBT ZIEL FÜR JOHNSON & JOHNSON AUF 180 (174) USD - 'BUY' |
| 12.09 15:49 | dpa-AFX: Janssen-Cilag Announces First EMA Submission For Nipocalimab |
| 12.09 15:36 | dpa-AFX: *J&J SEEKS EU APPROVAL FOR NIPOCALIMAB TO TREAT ANTIBODY-POSITIVE GENERALISED MYASTHENIA GRAVIS |
| 12.09 03:01 | dpa-AFX: J&J's TREMFYA Receives FDA Approval For Moderately To Severely Active Ulcerative Colitis In Adults |
| 11.09 05:39 | dpa-AFX: J&J's Dexamethasone Regimen Reduces Infusion Reactions In EGFR-Mutated NSCLC Patients On RYBREVANT |
|
|
